These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 33805422)

  • 61. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chimeric antigen receptor engineered natural killer cells for cancer therapy.
    Zhang Y; Zhou W; Yang J; Yang J; Wang W
    Exp Hematol Oncol; 2023 Aug; 12(1):70. PubMed ID: 37563648
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
    Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
    Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
    J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.
    Peng L; Sferruzza G; Yang L; Zhou L; Chen S
    Cell Mol Immunol; 2024 Oct; 21(10):1089-1108. PubMed ID: 39134804
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia.
    Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
    Cancer Lett; 2023 Apr; 558():216103. PubMed ID: 36805460
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
    Pratap S; Zhao ZJ
    Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia.
    Pasvolsky O; Daher M; Alatrash G; Marin D; Daver N; Ravandi F; Rezvani K; Shpall E; Kebriaei P
    Front Oncol; 2021; 11():800110. PubMed ID: 35083154
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

  • 73. IPSC-derived CAR-NK cells for cancer immunotherapy.
    Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
    Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
    Bexte T; Botezatu L; Miskey C; Gierschek F; Moter A; Wendel P; Reindl LM; Campe J; Villena-Ossa JF; Gebel V; Stein K; Cathomen T; Cremer A; Wels WS; Hudecek M; Ivics Z; Ullrich E
    Mol Ther; 2024 Jul; 32(7):2357-2372. PubMed ID: 38751112
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.
    Branella GM; Lee JY; Okalova J; Parwani KK; Alexander JS; Arthuzo RF; Fedanov A; Yu B; McCarty D; Brown HC; Chandrakasan S; Petrich BG; Doering CB; Spencer HT
    Front Immunol; 2023; 14():1294555. PubMed ID: 38022523
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
    Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
    Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
    Albinger N; Pfeifer R; Nitsche M; Mertlitz S; Campe J; Stein K; Kreyenberg H; Schubert R; Quadflieg M; Schneider D; Kühn MWM; Penack O; Zhang C; Möker N; Ullrich E
    Blood Cancer J; 2022 Apr; 12(4):61. PubMed ID: 35418180
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.